Cracking the Code: Understanding Analyst Reviews at Quest Diagnostics

Over the past three months, seven analysts have released ratings on Quest Diagnostics Inc (NYSE:DGX), offering diverse opinions ranging from optimistic to pessimistic.
This table presents an accurate representation of recent ratings by analysts, providing insights into changing sentiment over the last 30 days and drawing comparisons between previous months.

As usual, ratings were fairly mixed for these stocks: Bullish (26 out of 36 ratings were Bullish); Indifferent (10), Slight Bearish (9), Somewhat Bearish (16 of 26 ratings were Indifferent), Somewhat Bearish (17 of 26), Bearish (15 out of 26 ratings were Bearish). These ratings cover all 30 days over which ratings could have been updated: 1, 0s for one month ago = 0. One Month Ago = 2 MGAgo and were last updated during January 2018 @ 21 MGAgo = 0, with last 30 Days = 0. In terms of ratings; Last 30D for 1 M Ago= 0 as of today = 1, 0 for this 30 Day Report +30D | 6 Month Ago = 0, 4M Ago = 0, and so 4M Ago = 0.
Analysts provide valuable insight through assessments of 12-month price targets, with analysts reporting an average target price estimate of $1549.71 that exceeds its previous average target price estimate of $143.43. This represents an increase of 4.38% since this current average surpasses that of 143.43 set by prior analysts.

Deciphering Analyst Ratings: An Extended Look
Recent analyst actions provide us with an in-depth insight into how financial experts view Quest Diagnostics. Below is a detailed snapshot of key analysts, their recent evaluations, adjustments to ratings and price targets as well as current price targets: from Eric Coldwell Baird raising Neutral rating by $153.00 towards $155.00 to JP Morgan raising Equal-Weight targets to increase by PS144.00 ($138). Patrick Donnelly of Citigroup raised Equal Weight $144.00 against Patrick Donnelly UBS raised Equal-Weight $145.00 whilst Pat Donnelly was Bullish in $144.00 against Patrick Caliendo UBS Raised Neutral1 46.00 $139.00 Patrick Donnelly Citigroup Citigroup Raised Neutral150 Hold $150.00 whilst Ann Hynes Mizuho Raised Buy1550.00 $145.00 towards 150 USD
Key Insights:
Action Taken: Responding to changing market dynamics and company performance, analysts adjust their recommendations in response to recent Quest Diagnostics developments by either maintaining, raising or lowering their recommendations; such updates provide insight into analysts’ perspectives of Quest’s current state.
Analyst Ratings: After studying trends, analysts provide qualitative evaluations on Quest Diagnostics that range from “Outperform” to “Underperform”, communicating expectations regarding its relative performance compared with that of its wider market peers.
Price Targets: To gain insights, analysts provide estimates for the future value of Quest Diagnostics stock and use this as an opportunity to spot trends in analysts’ expectations over time.

Analysis of analyst evaluations can give an in-depth picture of Quest Diagnostics’ market position. With our Ratings Table’s help, stay informed and make data-driven decisions with ease. Also stay current with Quest Diagnostics analyst ratings!
Quest Diagnostics, the world’s premier independent provider of diagnostic testing, information, and services in the US. With nearly 95% of its revenue coming from clinical testing (clinical laboratory work, anatomic pathology testing services, esoteric testing) as well as substance abuse tests collected at its network of approximately 2,300 patient service centers as well as multiple doctors offices and hospitals, Quest also runs a smaller solutions segment offering clinical trial testing, risk assessments services and information technology solutions – while keeping its overall market presence intact through global expansion efforts and partnerships.
Quest Diagnostics’ Financials

Its Market Capitalization: Quest Diagnostics’ market capitalization is above industry average in size relative to peers, which highlights both its significant scale and secure market presence.
Revenue Growth: Quest Diagnostics has experienced impressive quarterly revenue growth since 31 March, 2024, reaching 1.5% as measured against competitors and attaining growth lower than their industry’s average of 7.0% (31 March, 2024). This indicates a substantial boost to top-line earnings – this makes Quest diagnostics stand out among its counterparts with regards to growth rate in Health Care sectors as compared with average peers like Siemens Healthcare or others in that field.
Net Margin: Quest Diagnostics surpasses industry norms with their outstanding financial performance, boasting an 8.16% net margin that illustrates their cost control efforts and strong profitability.
Return on Equity (ROE): The company stands out among industry averages by boasting an outstanding Return on Equity rate of 3.03%; evidence of efficient allocation and use of equity capital.
Return on Assets (ROA): Quest Diagnostics has demonstrated its exceptional financial performance by surpassing industry norms with an exceptional Return on Assets of 1.38% ROA, making effective use of its assets for optimal returns.
Quest Diagnostics’s debt-to-equity ratio stands below industry norms at 0.83, signalling to investors that its use of debt financing has decreased while maintaining a healthier balance between debt and equity. This has the ability to give Quest Diagnostics an edge against competition when competing against large institutions for funding.
Understanding Analyst Ratings
Analysts specialize in reporting for specific stocks or sectors within banking and financial systems. Their work typically involves attending company conference calls and meetings, researching company financial statements and communicating with insiders before publishing “analyst ratings” of stocks they cover; generally these assessments occur every quarter.
Some analysts provide investors with additional guidance by making predictions regarding growth estimates, earnings projections and revenue projections – giving investors additional guidance when making investment decisions. Users of analyst ratings must keep in mind that such advice may vary based on human perspectives and may therefore lead to greater variance than expected.